Published in Clin Infect Dis on November 01, 2008
Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol (2009) 12.98
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis (2010) 2.14
Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection. PLoS One (2011) 1.98
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis. PLoS One (2015) 1.42
Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health (2011) 1.34
Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One (2013) 1.13
Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One (2014) 1.12
Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health (2013) 1.08
Use of the GenoType(R) MTBDRplus assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda. BMC Clin Pathol (2010) 1.05
Tuberculosis in Sudan: a study of Mycobacterium tuberculosis strain genotype and susceptibility to anti-tuberculosis drugs. BMC Infect Dis (2011) 0.95
Characteristics of multidrug-resistant tuberculosis in Namibia. BMC Infect Dis (2012) 0.94
"Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Serv Res (2014) 0.92
Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis. PLoS One (2012) 0.90
High prevalence of primary multidrug resistant tuberculosis in persons with no known risk factors. PLoS One (2011) 0.90
Epidemiology and genetic diversity of multidrug-resistant tuberculosis in East Africa. Tuberculosis (Edinb) (2013) 0.86
Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia. BMC Public Health (2015) 0.86
First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis. Public Health Action (2014) 0.84
Aetiology of pulmonary symptoms in HIV-infected smear negative recurrent PTB suspects in Kampala, Uganda: a cross-sectional study. PLoS One (2013) 0.83
Association between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistance. PLoS One (2013) 0.79
Utility of the REBA MTB-Rifa® assay for rapid detection of rifampicin resistant Mycobacterium tuberculosis. BMC Infect Dis (2013) 0.78
Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis (2015) 0.78
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. Am J Trop Med Hyg (2015) 0.77
Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda. BMC Infect Dis (2009) 0.76
Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist (2017) 0.75
Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: A Retrospective Study. Medicine (Baltimore) (2016) 0.75
The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. PLoS Comput Biol (2016) 0.75
Prevalence of positive tuberculin skin test and associated factors among Makerere medical students, Kampala, Uganda. Afr Health Sci (2015) 0.75
The Relationship between Extensively Drug-Resistant Tuberculosis and Multidrug-Resistant Gram-Negative Bacilli. PLoS One (2015) 0.75
Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China. PLoS One (2015) 0.75
Tuberculosis retreatment 'others' in comparison with classical retreatment cases; a retrospective cohort review. BMC Public Health (2015) 0.75
Genotypic Detection of rpoB and katG Gene Mutations Associated with Rifampicin and Isoniazid Resistance in Mycobacterium Tuberculosis Isolates: A Local Scenario (Kelantan). Malays J Med Sci (2016) 0.75
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol (1993) 45.22
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA (2000) 8.42
Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep (2006) 7.90
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
WHO's new Stop TB Strategy. Lancet (2006) 5.59
Global incidence of multidrug-resistant tuberculosis. J Infect Dis (2006) 5.42
Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". BMJ (1998) 4.79
Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med (2005) 3.75
Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis (2001) 3.51
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis (1998) 3.43
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis (2003) 2.92
Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis (2000) 2.71
The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis (2004) 2.64
Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2000) 2.50
Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis (1993) 2.36
Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet (2005) 1.90
Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis (2007) 1.76
Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis (2007) 1.62
M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol (2007) 1.57
Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control? Am J Respir Crit Care Med (2004) 1.37
Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis (2006) 1.31
Anti-tuberculosis drug resistance surveillance in Uganda 1996-1997. Int J Tuberc Lung Dis (1999) 1.27
Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis (1998) 1.22
Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med (1994) 1.22
Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med (2000) 1.15
Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001. Int J Tuberc Lung Dis (2004) 1.09
Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda. East Afr Med J (2000) 1.08
Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis (2004) 1.06
Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol (2003) 1.04
Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis (2002) 0.98
[Rifomycin levels in the lung and tuberculous lesions in man]. Acta Tuberc Pneumol Belg (1969) 0.94
Evidence of 'amplifier effect' in pulmonary multidrug-resistant tuberculosis: report of three cases. Int J Infect Dis (2007) 0.84
Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol (2009) 12.98
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 6.22
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health (2009) 4.69
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Perpetration of partner violence and HIV risk behaviour among young men in the rural Eastern Cape, South Africa. AIDS (2006) 4.45
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis (2013) 4.26
Risk factors for domestic violence: findings from a South African cross-sectional study. Soc Sci Med (2002) 3.90
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ (2010) 3.31
Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ (2007) 3.30
Transactional sex with casual and main partners among young South African men in the rural Eastern Cape: prevalence, predictors, and associations with gender-based violence. Soc Sci Med (2007) 3.29
Rape of girls in South Africa. Lancet (2002) 3.16
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr (2010) 2.83
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 2.69
Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med (2003) 2.59
Obstacles to conducting epidemiological research in the UK general population. BMJ (2004) 2.59
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood (2010) 2.49
Ascertaining the size of the symptom iceberg in a UK-wide community-based survey. Br J Gen Pract (2011) 2.33
Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis (2011) 2.32
Validation of the diagnosis of autism in general practitioner records. BMC Public Health (2004) 2.22
Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother (2005) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Wound healing with honey--a randomised controlled trial. S Afr Med J (2006) 2.16
Multidrug-resistant tuberculosis. BMC Infect Dis (2008) 2.13
Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 2.10
Use of antenatal services and delivery care in Entebbe, Uganda: a community survey. BMC Pregnancy Childbirth (2007) 2.08
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 2.06
Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS (2014) 2.05
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 2.04
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2010) 2.04
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med (2009) 2.03
Guidance on the management of pain in older people. Age Ageing (2013) 2.02
MMR vaccination and pervasive developmental disorders: a case-control study. Lancet (2004) 2.02
Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res (2008) 1.97
HIV risk perception and prevalence in a program for prevention of mother-to-child HIV transmission: comparison of women who accept voluntary counseling and testing and those tested anonymously. J Acquir Immune Defic Syndr (2005) 1.96
Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med (2010) 1.95
Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis (2009) 1.92
CT-derived estimation of cochlear morphology and electrode array position in relation to word recognition in Nucleus-22 recipients. J Assoc Res Otolaryngol (2002) 1.91
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood (2010) 1.89
NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res (2010) 1.87
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr (2010) 1.81
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer (2010) 1.80
Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis (2004) 1.76
The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ (2004) 1.76
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 1.76
Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine (2007) 1.74
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71
Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ (2004) 1.69
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis (2004) 1.67
Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis (2010) 1.66
Associations between mild-to-moderate anaemia in pregnancy and helminth, malaria and HIV infection in Entebbe, Uganda. Trans R Soc Trop Med Hyg (2007) 1.66
A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15-24 in South Africa: results of the baseline survey. Trop Med Int Health (2005) 1.65
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res (2009) 1.65
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS (2004) 1.65
Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol (2007) 1.64
Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr (2014) 1.61
A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J (2007) 1.60
Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol (2010) 1.59
Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis (2002) 1.59
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine (2009) 1.59
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 1.58
The incubation period of kuru. Epidemiology (2002) 1.56
SpolPred: rapid and accurate prediction of Mycobacterium tuberculosis spoligotypes from short genomic sequences. Bioinformatics (2012) 1.56
Contact investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis (2013) 1.56
MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. Vaccine (2008) 1.55
Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med (2012) 1.55